GSA Capital Partners LLP Purchases Shares of 18,694 TG Therapeutics, Inc. $TGTX

GSA Capital Partners LLP acquired a new stake in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 18,694 shares of the biopharmaceutical company’s stock, valued at approximately $1,027,000.

Other large investors have also modified their holdings of the company. Man Group plc raised its position in shares of TG Therapeutics by 621.5% during the third quarter. Man Group plc now owns 1,008,462 shares of the biopharmaceutical company’s stock worth $36,431,000 after purchasing an additional 868,697 shares during the period. BNP Paribas Financial Markets boosted its position in shares of TG Therapeutics by 856.6% in the 4th quarter. BNP Paribas Financial Markets now owns 683,653 shares of the biopharmaceutical company’s stock valued at $20,380,000 after purchasing an additional 612,189 shares during the period. Dimensional Fund Advisors LP boosted its position in shares of TG Therapeutics by 129.5% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,084,855 shares of the biopharmaceutical company’s stock valued at $36,029,000 after purchasing an additional 612,068 shares during the period. Bank of America Corp DE increased its stake in TG Therapeutics by 71.7% in the 1st quarter. Bank of America Corp DE now owns 1,461,302 shares of the biopharmaceutical company’s stock worth $48,544,000 after purchasing an additional 610,195 shares in the last quarter. Finally, Goldman Sachs Group Inc. increased its stake in TG Therapeutics by 35.0% in the 4th quarter. Goldman Sachs Group Inc. now owns 2,051,132 shares of the biopharmaceutical company’s stock worth $61,144,000 after purchasing an additional 531,759 shares in the last quarter. 58.58% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

TGTX has been the subject of a number of analyst reports. JPMorgan Chase & Co. upped their price objective on shares of TG Therapeutics from $65.00 to $72.00 and gave the company an “overweight” rating in a research note on Friday, August 7th. B. Riley Financial lifted their target price on shares of TG Therapeutics from $55.00 to $86.00 and gave the stock a “buy” rating in a research report on Monday, July 27th. Bank of America boosted their price target on shares of TG Therapeutics from $17.00 to $20.00 and gave the company an “underperform” rating in a report on Tuesday, July 7th. Jefferies Financial Group restated a “buy” rating and issued a $83.00 price target on shares of TG Therapeutics in a research report on Monday, June 22nd. Finally, Weiss Ratings reaffirmed a “hold (c+)” rating on shares of TG Therapeutics in a research note on Wednesday, July 29th. Five analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $63.00.

TG Therapeutics Price Performance

NASDAQ TGTX opened at $49.28 on Tuesday. The company has a 50 day simple moving average of $52.64 and a 200-day simple moving average of $40.37. The company has a debt-to-equity ratio of 1.23, a current ratio of 4.27 and a quick ratio of 3.72. The firm has a market capitalization of $7.54 billion, a price-to-earnings ratio of 17.99, a price-to-earnings-growth ratio of 2.09 and a beta of 1.62. TG Therapeutics, Inc. has a 52-week low of $26.76 and a 52-week high of $59.30.

TG Therapeutics (NASDAQ:TGTX) last posted its quarterly earnings results on Monday, August 3rd. The biopharmaceutical company reported $0.05 EPS for the quarter, missing the consensus estimate of $0.31 by ($0.26). TG Therapeutics had a return on equity of 73.49% and a net margin of 55.22%.The company had revenue of $240.34 million for the quarter, compared to analyst estimates of $229.77 million. During the same quarter in the prior year, the business posted $0.17 earnings per share. The business’s revenue for the quarter was up 70.2% compared to the same quarter last year. Equities research analysts predict that TG Therapeutics, Inc. will post 0.92 earnings per share for the current fiscal year.

TG Therapeutics Company Profile

TG Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company’s research strategy focuses on the modulation of B-cell biology through novel antibody and small‐molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.

In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.